Technology Development Recent Happenings

In the first half of FY 2016, NIAID recognized the following individuals for their contributions to the first U.S. patents issued in a patent family.

United States Patent 9,133,480 was issued on September 15, 2015, for Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites. NIAID inventors: Bernard Moss, M.D., Ph.D., Linda Wyatt, Ph.D.; Patricia Earl, Ph.D

United States Patent 9,181,530 was issued on November 10, 2015, for Infectious hepatitis E virus genotype 3 recombinants. NIAID inventors: Hanh T. Nguyen.

United States Patent 9,193,790 was issued on November 24, 2015, for Use of antagonists of the interaction between HIV GP120 and A4B7 integrin. NIAID inventors: James Arthos, Ph.D., Claudia Cicala, Ph.D., Anthony S. Fauci, M.D.

United States Patent 9,259,463 was issued on February 16, 2016, for Chlamydia vaccine. NIAID inventors: Harlan D. Caldwell, Ph.D., Deborah D. Crane

United States patent 9,273,121 was issued on March 1, 2016, for Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use NIAID inventors: Robert H. Purcell, M.D. (retired)

United States patent 9,273,124 was issued on March 1, 2016, for Monoclonal antibodies that react with the capsule of Bacillus anthracis. NIAID inventors: Zhaochun Chen, Ph.D.

United States patent 9,255,252 was issued on February 9, 2016 for Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae. NIAID inventors: Stephen Whitehead, Ph.D.

United States patent 9,238,799 was issued on January 19, 2016, for Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses. NIAID inventors: Alexander G. Pletnev, Ph.D., D.Sci.

United States patent 9,228,002 was issued on January 5, 2016, for Leishmania vaccine using sand fly salivary immunogen. NIAID inventors: Shaden Kamhawi, Ph.D., Jesus Valenzuela, Ph.D., Jose Ribeiro, M.D., Ph.D.

United States patent 9,175,070 was issued on November 3, 2015, for Neutralizing antibodies to HIV-1 and their use. NIAID inventors: John R. Mascola, M.D., Xueling Wu, Ph.D., Mario Roederer, Ph.D., Peter D. Kwong, Ph.D., Tongqing Zhou, Ph.D., Mark Connors, M.D.

NIAID and Matinas BioPharma Holding, Inc. signed a clinical cooperative research and development agreement (CRADA) for Development of Cochleate Technology for the Treatment of Serious Infections. NIAID principal investigator: Steven M. Holland, M.D.

NIAID and PepTCell Limited (SEEK) signed a clinical cooperative research and development agreement (CRADA) for Phase II Study of the Efficacy and Safety of FLU-v, PepTCell Limited's Proprietary Peptide-Based Universal Influenza Vaccine Containing Conserved T Cell Epitopes. NIAID principal investigator: Jeffery Taubenberger, M.D., Ph.D.

NIAID and GlaxoSmithKline signed a clinical cooperative research and development agreement (CRADA) for Collaboration to develop broadly-neutralizing antibodies against HIV-1 from NIAID for use with anti-retrovirals owned by GSK. NIAID principal investigator: Mark Connors, M.D. and Richard Koup, M.D.

NIAID and Bristol-Myers Squibb Company (BMS) signed a materials cooperative research and development agreement (MCRADA) to provide up to 50 mg recombinant human Fc fragment of immunoglobulin G4 (IgG4)/ NIAID principal investigator: Peter D. Sun, Ph.D.

NIAID and Bristol-Myers Squibb Company (BMS) signed a materials cooperative research and development agreement (MCRADA) for Structural Determination of Bristol-Meyers Squibb Company HIV Attachment Inhibitors in Complex with HIV-1 Envelope Glycoprotein.

NIAID principal investigator: Peter Kwong, Ph.D.

NIAID and Symmune Therapeutics LLC signed a cooperative research and development agreement (CRADA) for determine feasibility and effectiveness of using baterially derived products as immunomodulatory agents for the development of therapeutics for the prevention and treatment of respiratory diseases. NIAID principal investigator: Helene F. Rosenberg, M.D., Ph.D.

NIAID and Matinas BioPharma Holding, Inc. signed a cooperative research and development agreement (CRADA) for Development of Matinas' Encochleation of Amphotericin B (CAMB) for the Treatment of Cryptococcal Meningitis NIAID principal investigator: Peter Williamson, M.D., Ph.D.

NIAID and Viamet Pharmaceuticals, Inc. signed a cooperative research and development agreement (CRADA) for Preclinical Efficacy Evaluation of Viamet Pharmaceutical's Proprietary Antifungal Compounds VT-1129 and/or VT-1161 in Oropharyngeal Candidiasis. NIAID principal investigator: Michail S. Lionakis, M.D., Sc.D.

NIAID and Amgen Inc. signed a cooperative research and development agreement (CRADA) for Development of a therapeutic against inflammation, cancer, and fibrosis using Amgen, Inc.'s proprietary Anti-muCSF1R antibodies. NIAID principal investigator: Thomas A. Wynn, Ph.D.

NIAID and Carilion Medical Center (CMC) signed an external research collaboration agreement (RCA) for Evaluation of the Molecular Factors Contributing to Staphylococcus epidermidis Colonization of the Skin. NIAID principal investigator: Michael Otto, Ph.D.

NIAID and Ionis Pharmaceuticals, Inc. signed an external research collaboration agreement (RCA) for Antisense oligonucleotides targeted to mouse prion protein (p27-30). NIAID principal investigator: Byron Caughey, Ph.D.

NIAID, Biomedical Advanced Research and Development Authority (BARDA) (DHHS) and Sanofi Pasteur Inc. signed an external research collaboration agreement (RCA) for an inactivated influenza H5N1 vaccine for use in primate studies. NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.

NIAID and Genentech. Inc. signed an external research collaboration agreement (RCA) for Multiplex immunohistochemical analysis of immune cell populations by histocytometry. NIAID principal investigator: Ronald N. Germain, M.D., Ph.D.

NIAID and Sanaria, Inc., Antigen Discovery Inc. and Duke University signed a human research collaboration agreement (RCA) to isolate and express monoclonal antibodies collected after immunization with their vaccine. Antibodies will be screened for malaria inhibitory activity and specificity. NIAID principal investigator: Robert Seder, M.D.

NIAID and Merck, Sharp, and Dohme signed a human research collaboration agreement (RCA) for the validation of the genetic and molecular associations of the genes involved in a novel Mendelian autoimmune disease. NIAID principal investigator: Michael J. Lenardo, M.D.

NIAID and Dartmouth College, and Adimab, LLC signed a human research collaboration agreement (RCA) for recombinant protein (antibody) isolated from RSV donors. NIAID principal investigator: Barney Graham, M.D., Ph.D.

NIAID and Mahidol University signed a human research collaboration agreement (RCA) for a comparative study of intestinal carriage of multidrug-resistant bacteria between healthy population and patients. NIAID principal investigator: Michael Otto, Ph.D.

NIAID and Yale University School of Medicine signed a human research collaboration agreement (RCA) to transfer human PBMC samples from pediatric systemic capillary leak syndrome (SCLS). NIAID principal investigator: Kirk M. Druey, M.D.

NIAID and Selecta Biosciences signed a research collaboration agreement (RCA) to develop a nanoparticle vaccine using Pfs25 protein as the antigen. NIAID principal investigator: Patrick E. Duffy, M.D.

NIAID and Fred Hutchinson Cancer Research Center (FHCRC), Juno Therapeutics and Seattle Children's Hospital (Seattle Children's Research Institute) signed a research collaboration agreement (RCA) to develop CART that uses VRC07. NIAID principal investigator: John R. Mascola, M.D.

NIAID and GlaxoSmithKline Biologicals SA (GSK) signed a research collaboration agreement (RCA-S) to investigate the suitability of GSK’s Adjuvant System AS01 for formulation of recombinant protein conjugates. NIAID principal investigator: Patrick E. Duffy, M.D.

NIAID and Merck, Sharp, and Dohme signed a research collaboration agreement (RCA) to collect Borrelia nymphal ticks, complete genome of Ixodes scapularis, and sequence messenger RNA. NIAID principal investigator: Jose Ribeiro, M.D., Ph.D., Jesus G. Valenzuela, Ph.D.

NIAID and Walter Reed Army Institute of Research (WRAIR) (DoD) signed a research collaboration agreement (RCA) to evaluate pre-erythrocytic vaccine antigens (PEVA) for their ability to provide sterile protection in mice. NIAID principal investigator: Patrick E. Duffy, M.D.

NIAID and Bharat Biotech Intl. Ltd signed a research collaboration agreement (RCA) to optimize the baculovirus-based production of a stabilized version of RSV F glycoprotein for evaluation of vaccine immunogenicity. NIAID principal investigator: Barney Graham, M.D., Ph.D.

NIAID and Baylor College of Medicine signed a research collaboration agreement (RCA) to collaborate on a new cell culture system for noroviruses. NIAID principal investigator: Kim Y. Green, Ph.D.

NIAID and Stanford University signed a research collaboration agreement (RCA) for use of structure-based design to develop effective Hepatitis C vaccines. NIAID principal investigator: Peter Kwong, Ph.D.

NIAID and ARMS Pharmaceutical signed a research collaboration agreement (RCA) to confirm the efficacy of a compound ARMS-I, as previously demonstrated in mouse model and humans. NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.

NIAID and National Institutes of Biomedical Innovation, Health and Nutrition signed a research collaboration agreement (RCA-S) to study antibody responses to Epstein-Barr virus glycoprotein vaccine constructs in cynomolgus monkey. NIAID principal investigator: Jeffrey I. Cohen, M.D.

NIAID and Walter Reed Army Institute of Research (WRAIR) (DoD) signed a research collaboration agreement (RCA) for use in vivo studies to identify how adaptive T-cell dependent antibody responses control the persistence of high antibody levels after vaccination. NIAID principal investigator: Ronald N. Germain, M.D., Ph.D.

NIAID and Scripps Research Institute signed a research collaboration agreement (RCA) for the development of reagents and methods to support coronavirus vaccine development. NIAID principal investigator: Barney Graham, M.D., Ph.D.

NIAID and ARNO Therapeutics signed a research collaboration agreement (RCA-S) to use in vitro and in vivo models of human prion infection. NIAID principal investigator: Suzette A. Priola, Ph.D.

NIAID and Lipotek Pty Ltd signed a research collaboration agreement (RCA-S) to test VRC's bovine RSV F prefusion immunogens. NIAID principal investigator: Peter Kwong, Ph.D.

NIAID and Statens Serum Institut and Radboud University Nijmegen Medical Centre signed a research collaboration agreement (RCA-S) for Pfs48/45-EPA vaccine project. NIAID principal investigator: Patrick E. Duffy, M.D.

NIAID and University of Minnesota signed a research collaboration agreement (RCA-S) to perform studies on the activity of Chimeric Antigen Receptors (CARs). NIAID principal investigator: Edward A. Berger, Ph.D.

NIAID, PATH Malaria Vaccine Initiative and GlaxoSmithKline signed a research collaboration agreement (RCA) for a repeat dose toxicity study in New Zealand white rabbits for conjugate malaria vaccines. NIAID principal investigator: Patrick E. Duffy, M.D.

NIAID and Albert Einstein College of Medicine, Inc. signed a research collaboration agreement (RCA) to establish recombinant eGFP-expressing vesiculoviruses (VSV). NIAID principal investigator: Peter Jahrling, Ph.D.

NIAID and University of Pennsylvania School of Medicine signed a research collaboration agreement (RCA) are focused on novel mRNA-based vaccine delivery methods/techniques. NIAID principal investigator: Barney Graham, M.D., Ph.D.

NIAID and Sanofi US Services Inc. signed a research collaboration agreement (RCA-S) to develop Zika virus vaccine candidat. NIAID principal investigator: Barney Graham, M.D., Ph.D.

NIAID and Fudan University signed a research collaboration agreement (RCA) to screen specific antibodies against the recombinant protein antigens of various pathogens that causing infectious disease, especially HIV. NIAID principal investigator: Peter Kwong, Ph.D.

NIAID and University of Hawaii signed a research collaboration agreement (RCA) to test the ability of prime-boost Ebola and other Filovirus vaccines to elicit a compatible immunogenicity profile in non- human primates. NIAID principal investigator: Nancy Sullivan, Ph.D.